Document Type

Article

Publication Date

5-31-2022

DOI

10.3233/JAD-220264

Publication Title

Journal of Alzheimer's Disease

First Page

999

Last Page

1001

Volume

87

Issue

3

College/School

School of Medicine

Abstract

U.S. Food and Drug Administration-s (FDA) approval of aducanumab (Aduhelm® in the US) as a treatment for mild cognitive impairment of the Alzheimer type and Alzheimer-s disease has raised such major concerns about efficacy, safety, FDA processes, and regulatory capture that Biogen-s license to market this biologic should be immediately withdrawn. Aducanumab has not demonstrated benefit to patients, failed to meet regulatory guidelines, and is likely to cause both individual and societal harm.

Rights

© Whitehouse & Vikas, 2022. The definitive, peer reviewed and edited version of this article is published in Journal of Alzheimer's Disease, vol. 87, no. 3, pp. 999-1001, 2022, https://doi.org/10.3233/JAD-220264.

Comments

This is an Accepted Manuscript of an article published by IOS Press in the Journal of Alzheimer's Disease on May 31, 2022, available at: https://doi.org/10.3233/JAD-220264

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.